DAIC

JUNE 4, 2024

Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment 5. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) 10. Tenax Therapeutics Announces New U.S.

Preserved Ejection Fraction 105

Preserved Ejection Fraction Peripheral Arterial Disease Heart Failure Atrial Fibrillation 105

Circulation

JANUARY 22, 2025

Circulation, Ahead of Print. Optimal NT-proBNP cut points for HFpEF rule out (optimizing sensitivity) and rule in (optimizing specificity) were derived and tested, stratified by obesity and atrial fibrillation.

Preserved Ejection Fraction 55

Preserved Ejection Fraction Outpatient Heart Failure BMI 55

European Journal of Heart Failure

OCTOBER 30, 2023

In patients with heart failure with preserved ejection fraction (HFpEF), abnormal global longitudinal strain (GLS) is a strong predictor for clinical events and can help identity patients who are at risk for future decline in left ventricular ejection fraction (LVEF). After a median follow-up of 4.6 years,

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Outcomes Hospital 40

Circulation

NOVEMBER 11, 2024

As heart failure with preserved ejection fraction (HFpEF) comprises half of all heart failure cases, understanding its management and effect on outcomes is crucial. Multivariate logistic and linear regression analyses were performed, adjusting for multiple patient and hospital confounders.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Inpatient Heart Failure Cardiogenic Shock 40

Journal of Cardiovascular Electrophysiology

DECEMBER 17, 2024

Abstract Background Heart failure (HF) with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are associated with high morbidity and mortality. HFpEF were defined as HFA-PEFF score of 5 or 6 and left ventricular ejection fraction 50% before the initial CA. 423 by a log-rank test).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 40

Journal of Cardiovascular Electrophysiology

FEBRUARY 13, 2024

Contemporary classification of HF categorizes it into HF with reduced ejection fraction (HFrEF), HF with mildly reduced ejection fraction (HFmrEF), and HF with preserved ejection fraction (HFpEF). Aggregate data comparing the risk profile of AF between these three HF categories are lacking.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Hospital 40

European Journal of Heart Failure

NOVEMBER 29, 2023

Methods Between 1 November 2018 and 31 December 2020, 10 162 patients with chronic or acute/worsening HF with reduced, mildly reduced, or preserved ejection fraction were enrolled from 220 centres in 41 European or ESC affiliated countries.

Heart Failure 75

Heart Failure Preserved Ejection Fraction Quality of Life Biomarkers 75

European Journal of Heart Failure

MARCH 4, 2024

Patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) have a high risk of developing LRTI. CI, confidence interval; HR, hazard ratio. Aims Lower respiratory tract infections (LRTI) are common worldwide. Cox regression was used to study the effect of empagliflozin on incident LRTI.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure COVID-19 Kidney Disease 40

DAIC

JUNE 21, 2024

The investigators concluded that INPEFA is a cost-effective addition to standard of care for patients hospitalized with heart failure and comorbid diabetes. According to the research results, the use of INPEFA led to a net gain in QALYs of 0.425 for INPEFA versus standard of care. healthcare system,” said Craig Granowitz, M.D.,

Heart Failure 105

Heart Failure Preserved Ejection Fraction Diabetes Research 105

HeartRhythm

APRIL 30, 2024

Atrial fibrillation (AF) with comorbid heart failure with preserved ejection fraction (HFpEF) presents a significant management challenge. While the association between AF and heart failure with reduced ejection fraction is extensively studied, the correlation between AF and HFpEF remains less explored.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Hospital 40

HeartRhythm

APRIL 30, 2024

Previous studies have demonstrated significant morbidity and mortality in patients with heart failure (HF) with reduced ejection fraction (HFrEF), particularly with accompanying atrial fibrillation (AF).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 40

HeartRhythm

JUNE 23, 2024

Furthermore, among patients with heart failure, both reduced and preserved ejection fraction, catheter ablation reduces heart failure hospitalizations and mortality.1-10

Preserved Ejection Fraction 40

Preserved Ejection Fraction Ablation Atrial Fibrillation Heart Failure 40

HeartRhythm

MARCH 31, 2025

A 76-year-old male with heart failure and preserved ejection fraction presented with recurrent falls. He underwent dual-chamber pacemaker placement at an outside hospital. An implantable loop recorder revealed profound sinus bradycardia, AF and offset sinus pauses.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Pacemaker Bradycardia Heart Failure 40

JAMA Cardiology

SEPTEMBER 30, 2021

This cohort study examines the prevalence of epicardial coronary artery disease and coronary microvascular dysfunction in hospitalized patients with heart failure with preserved ejection fraction.

Coronary Artery Disease 40

Coronary Artery Disease Preserved Ejection Fraction Heart Failure Hospital 40

Circulation: Cardiovascular Quality & Outcomes

APRIL 21, 2025

We then assessed the real-world generalizability of TOPCAT by developing a novel statistic, the phenotypic distance metric, to quantify the representation of TOPCAT participants within EHR patients.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Cardiac Function Hospital 40

JAMA Cardiology

JULY 23, 2024

Among patients with heart failure with preserved ejection fraction (HFpEF), right ventricular (RV) dysfunction is strongly associated with an increased risk of morbidity and mortality.

Preserved Ejection Fraction 44

Preserved Ejection Fraction Heart Failure Pulmonary Exercise 44

Journal of the American Heart Association

JANUARY 19, 2024

BackgroundSystemic chronic inflammation plays a role in the pathophysiology of both heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction‐associated fatty liver disease. The study outcome was time to the first hospitalization for HF. In 10 019 middle‐aged individuals (mean age, 63.3±10.6

Heart Failure 45

Heart Failure Preserved Ejection Fraction Hospital Heart Disease 45

Frontiers in Cardiovascular Medicine

OCTOBER 10, 2024

MethodsFrom December 1, 2022 to February 1, 2024, 103 patients with heart failure were consecutively enrolled from the cardiology clinic or ward of the First Affiliated Hospital of Nanjing Medical University. Patients diagnosed with preserved ejection fraction (HFpEF) were treated with Vericiguat combined with “ARNI, BB, SGLT2i” therapy.

Heart Failure 52

Heart Failure Preserved Ejection Fraction Cardiac Function Quality of Life 52

Circulation

NOVEMBER 11, 2024

Left ventricular ejection fractions were similar in both MAC (58.3 + 11.9) Conclusion:Among patients hospitalized with ‘diastolic heart failure’ MAC is associated with worse cardiovascular outcomes. Conclusion:Among patients hospitalized with ‘diastolic heart failure’ MAC is associated with worse cardiovascular outcomes.

Heart Failure 40

Heart Failure Preserved Ejection Fraction Bicuspid/Mitral Outcomes 40

European Journal of Heart Failure

MARCH 30, 2025

We assessed the associations of MetS indices with echocardiographic parameters, biomarkers of myocardial damage (high-sensitivity cardiac troponin I [hs-cTnI] and B-type natriuretic peptide [BNP]) and incident HF hospitalizations including HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF).

Heart Failure 40

Heart Failure Preserved Ejection Fraction Biomarkers BMI 40

European Journal of Heart Failure

FEBRUARY 5, 2025

This effect was more pronounced in patients with HF with reduced ejection fraction ( p interaction <0.0001). Patients treated with ARNI had a lower risk of all-cause mortality (risk ratio [RR] 0.64; 95% CI 0.450.92; p =0.01) but had a similar rate of HF hospitalization (RR 0.71; 95% CI 0.431.18; p =0.19).

Kidney Disease 49

Kidney Disease Heart Failure Preserved Ejection Fraction Blood Pressure 49

DAIC

JANUARY 23, 2024

To date, no clinically relevant changes in serum sodium levels or progressive hyponatremia were observed and none of the patients needed to be hospitalized for congestion since the start of the study. At the start of the study treatment period, loop diuretics were withheld, and patients were treated with DSR 2.0

Heart Failure 104

Heart Failure Preserved Ejection Fraction Hypertension Cancer 104

European Journal of Heart Failure

APRIL 13, 2025

The beneficial effects of finerenone in patients with heart failure (HF) and mildly reduced or preserved ejection fraction were consistent, regardless of a history of chronic obstructive pulmonary disease (COPD) status.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Pulmonary Peripheral Arterial Disease 40

Journal of the American Heart Association

DECEMBER 14, 2024

The main outcome was the composite of allcause mortality and first HF hospitalization. The mean age, body mass index, left ventricular ejection fraction, and EAT volume were 57.0 During a median followup of 34 months, 169 patients (24.4%) died or were hospitalized for HF. Of 692 participants, 41.3% were women.

Preserved Ejection Fraction 58

Preserved Ejection Fraction Heart Failure Hospital Outcomes 58

DAIC

MARCH 26, 2025

live with HF, 2 a complex clinical syndrome with symptoms and signs that result from any structural or functional impairment of ventricular filling or ejection of blood. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. 4 Approximately 6.7 million adults in the U.S. Bozkurt A, et al.

Heart Failure 52

Heart Failure Preserved Ejection Fraction Kidney Disease ACE Inhibitor 52

Frontiers in Cardiovascular Medicine

FEBRUARY 6, 2025

This study aimed to evaluate the association between PWR and all-cause mortality within 30 days of hospitalization in ADHF patients from Jiangxi, China.MethodsA total of 1,453 ADHF patients from the Jiangxi-ADHF study1 cohort were included. The primary outcome measure was all-cause mortality within 30 days of hospitalization.

Heart Failure 40

Heart Failure Preserved Ejection Fraction Hospital Outcomes 40

European Journal of Heart Failure

DECEMBER 13, 2023

BMI, body mass index; CI, confidence interval; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide. ABSTRACT Aim Chronic obstructive pulmonary disease (COPD) is common in heart failure with a mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and is associated with worse outcomes.

Preserved Ejection Fraction 75

Preserved Ejection Fraction Heart Failure Pulmonary Quality of Life 75

Science Daily - Heart Disease

SEPTEMBER 2, 2024

Finerenone reduced the composite of total first and recurrent heart failure (HF) events (hospitalizations for HF or urgent HF visits) and cardiovascular death in patients with HF and mildly reduced or preserved ejection fraction, according to an international clinical trial.

Preserved Ejection Fraction 127

Preserved Ejection Fraction Heart Failure Hospital 127

European Journal of Heart Failure

DECEMBER 19, 2024

BNP, B-type natriuretic peptide; CV, cardiovascular; EF, ejection fraction; eGFR, estimated glomerular filtration rate; EP, endpoint; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SwedeHF, Swedish Heart Failure Registry; US, United States.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Outpatient Atrial Fibrillation 40

European Journal of Heart Failure

DECEMBER 7, 2023

ABSTRACT Background Left atrial (LA) myopathy is increasingly recognized as an important phenotypic trait in heart failure (HF) with preserved ejection fraction (HFpEF). Individuals with biatrial myopathy had an 84% higher risk of HF hospitalization or death as compared to those with isolated LA myopathy (HR 1.84; 95% CI, 1.16–2.92,

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Exercise Atrial Fibrillation 40

Journal of Cardiovascular Electrophysiology

OCTOBER 21, 2024

Abstract Introduction Catheter ablation for atrial fibrillation (AF) reduces heart failure (HF) hospitalization in patients with HF with preserved ejection fraction (HFpEF). The primary endpoint was a composite of death from any cause or hospitalization for worsening HF.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 40

European Journal of Heart Failure

DECEMBER 15, 2024

A summary of effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum. The primary composite outcome was total HF hospitalizations and cardiovascular (CV) death. All participants in PARAGON-HF were divided into three age groups: <65years, 6574years, and75years.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Laboratory Echocardiogram 40

European Journal of Heart Failure

FEBRUARY 18, 2024

Global longitudinal strain (GLS) and clinical outcomes in heart failure with preserved ejection fraction (HFpEF). Almost 47% of patients with HFpEF had evidence of left ventricular (LV) subclinical dysfunction, defined as absolute LV GLS 0.1).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Hospital Outcomes 40

European Journal of Heart Failure

FEBRUARY 5, 2025

Beta-blockers are commonly used in patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Methods and results We pooled individual patient data from four large HFmrEF/HFpEF trials (I-Preserve, TOPCAT, PARAGON-HF, and DELIVER).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Outcomes Atrial Fibrillation 40

DAIC

FEBRUARY 22, 2024

The study, which is testing a novel rehabilitation program designed for older patients hospitalized with acute heart failure, is funded by a five-year, $30 million grant , awarded to Wake Forest University School of Medicine in 2022 by the National Institute of Aging, part of the National Institutes of Health.

Heart Failure 105

Heart Failure Research Preserved Ejection Fraction Hospital 105

European Journal of Heart Failure

NOVEMBER 3, 2024

The role of ablation-based rhythm control in patients with AF and HF with preserved (HFpEF) or mildly reduced ejection fraction (HFmrEF) is not known. Methods CABA-HFPEF-DZHK27 (NCT05508256) is an investigator-initiated, prospective, randomized, open, interventional multicentre strategy trial with blinded outcome assessment.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 40

Journal of the American Heart Association

FEBRUARY 19, 2025

A secondary hierarchical outcome consisted of cardiovascular death, HF hospitalizations, urgent HF visits, and NTproBNP change. The primary end point was timeaveraged proportional change in NTproBNP (Nterminal proBtype natriuretic peptide) from baseline through weeks 4 and 8.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Hospital Heart Failure Outcomes 40